Bimagrumab is under clinical development by Eli Lilly and Co and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bimagrumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bimagrumab overview
Bimagrumab (BYM-338) is under development for the treatment of non-diabetic patients with obesity. Bimagrumab is administered as an intravenous infusion. It is a fully human HuCAL-based antibody which targets ActRIIB (activin receptor type-2B). It was also under development for cachexia in patients with chronic obstructive pulmonary disorder, type 2 diabtetes, stage IV non-small cell lung cancer or stage III/IV adenocarcinoma of the pancreas, musculoskeletal diseases such as sporadic inclusion body myositis (sIBM), hip fracture, sarcopenia, disuse muscle atrophy associated with femoral fracture, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF) and unspecified indications.
Eli Lilly and Co overview
Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops, and markets human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, autoimmune disorders, men’s health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company operates R&D facilities, and production and distribution facilities in North America, South America, Europe, the Middle East, Africa and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
For a complete picture of Bimagrumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
